Ambarish Shah
Chief Technology OfficerDr. Ambarish Shah, Ph.D., is Chief Technology Officer of DiaMedica Therapeutics Inc. from September 2023. Since May 2023, Dr. Shah has been advising DiaMedica as it worked through the final resolution of the clinical hold on the investigational new drug application for its ReMEDy2 clinical trial of DM199 in acute ischemic stroke patients. Dr. Shah has experience in advancing biopharmaceuticals from early stage to commercialization. He was previously the Vice President and Head of Global Vaccines Development at CSL Seqirus where he was accountable for end-to-end chemistry, manufacturing and control (CMC) in the development of vaccines. Prior to that position, he was Executive Director, Head of Drug Product Development at Bristol-Myers Squib (formerly Celgene). His prior experience comprised increasingly impactful roles at AstraZeneca (formerly MedImmune), GlaxoSmithKline (formerly Human Genome Sciences) and Pfizer (formerly Wyeth). Dr. Shah received his Bachelor of Pharmacy degree from Mumbai University, India and his Master of Science in Pharmaceutical Sciences from Duquesne University, Pittsburgh, PA. He obtained his doctorate in Pharmaceutical Sciences from Mercer University, Atlanta, Georgia with a focus on Drug Delivery.
Positions
- Company NameDiaMedica Therapeutics Inc.Stock CodeDMACPositionChief Technology OfficerColleagues
- DJDietrich John PaulsPresident, CEO & Director
- JTJames T. ParsonsIndependent Chairman
- SKScott KellenCFO & Corporate Secretary
- JKJulie KropChief Medical Officer
- DRDominic R. CundariChief Commercial Officer
- RMR. Michael GiuffreIndependent Director
- DJDaniel J. O'ConnorIndependent Director
- PBPhilip BathMember of Stroke Advisory Board
